Which injectable peptide is best for weight loss in the UK?

You've read the forums. Here's what the clinical evidence actually says.

The scene is familiar: you've spent an evening trawling Reddit threads and comparison articles, and you've seen names like tirzepatide, semaglutide, and a handful of research-stage compounds all described as the best injectable peptide for weight loss. It's worth cutting through that noise with what UK regulators and peer-reviewed trials have confirmed.

Two peptide-based injections are currently licensed in the UK for adult weight management. Tirzepatide, sold as Mounjaro by Eli Lilly, works on both GIP and GLP-1 receptors simultaneously, the only dual-agonist available here. Semaglutide, sold as Wegovy by Novo Nordisk, acts on the GLP-1 receptor alone. Both slow gastric emptying, reduce appetite, and are taken as a once-weekly injection under the skin. You can read a fuller explanation of how these medicines work on our guide to peptide injections for weight loss.

In the SURMOUNT-1 trial, participants on tirzepatide 15mg lost around 20–21% of their body weight over 72 weeks on average. The STEP 1 trial, published in the New England Journal of Medicine, found semaglutide 2.4mg produced roughly 15% average weight reduction over 68 weeks. Those figures come from controlled clinical conditions, they are not guarantees for any individual. Then came SURMOUNT-5: a direct head-to-head trial, 72 weeks, 751 adults with obesity but without type 2 diabetes, which found tirzepatide produced greater average weight loss than semaglutide 2.4mg. That evidence fed into NICE's appraisal of tirzepatide, published in December 2024.

Neither trial tells you which is right for you. That part takes a prescriber.

What separates tirzepatide from other injectable peptides, and why the dual mechanism matters

A reasonable question to ask is: why does acting on two receptors instead of one make a difference? GLP-1 receptor agonists reduce appetite partly by slowing how quickly the stomach empties and partly by signalling satiety to the brain. GIP receptor activation adds a complementary layer, it also plays a role in energy metabolism and appears to amplify the appetite-suppressing effect when combined with GLP-1 stimulation. The result, in the trial data, is a meaningfully larger average weight reduction.

Tirzepatide comes as a pre-filled KwikPen. Treatment starts at 2.5mg, a dose chosen for tolerability, giving the body time to adjust before stepping up. The prescriber guides titration from there, typically at four-week intervals, through 5mg, 7.5mg, 10mg, 12.5mg and up to 15mg if appropriate. You can see a broader overview of how weight-loss injectables work if you want the fuller picture on mechanism.

Semaglutide's titration pathway is similarly gradual: 0.25mg, 0.5mg, 1.0mg, 1.7mg, and then 2.4mg as the standard maintenance dose, though the MHRA approved a higher 7.2mg dose in early 2026 for adults with a BMI of 30 or above. Both medicines carry a Black Triangle (▼) designation, meaning the MHRA collects additional safety data as real-world use expands.

Other injectable peptides you may have encountered (AOD-9604, fragment 176-191, CJC-1295) are research-stage compounds. None holds a UK licence for weight management. Supplying them for weight loss falls outside regulated medicine. If you want to understand how peptides injections for weight loss are categorised in the UK, including which compounds are licensed and which are not, that distinction is worth reading up on before making any decisions.

Side effects, eligibility, and the questions our prescribers get asked most

Both medicines share a similar side-effect profile. Nausea is the most commonly reported, particularly in the early weeks or after a dose increase. Other gastrointestinal effects (loose stools, constipation, reflux, burping) are also common and tend to settle as the body adjusts. Fatigue, headache and injection-site reactions appear less frequently. The NHS tirzepatide page and its semaglutide equivalent give thorough, patient-level detail on what to watch for.

A January 2026 MHRA Drug Safety Update highlighted acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines: severe stomach pain that extends to the back (with or without vomiting) warrants urgent medical attention. That update also reinforced the advice that any suspected side effect, or any pen you think may not be genuine, can be reported at the MHRA's Yellow Card scheme.

On eligibility: the licensed threshold for both medicines is a BMI of 30 or above, or 27 or above if you have at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone never determines whether treatment is appropriate, a prescriber considers the full clinical picture, including any conditions that would make these medicines unsuitable. Neither medicine is licensed for use during pregnancy, breastfeeding, or for those trying to conceive, and they are not licensed for under-18s.

A note on oral alternatives: if the injection itself is what gives you pause, it is worth knowing that semaglutide is now also available as a daily tablet (Wegovy tablets, approved by the MHRA in June 2026). That route involves no injection at all. If you are still weighing up the options, our page on which injectable is best for weight loss walks through the key differences between tirzepatide and semaglutide to help you have a more informed conversation with a prescriber. You can also explore how weight-loss injections compare to other formats if that comparison would help you decide.

Getting a prescription through a regulated UK pharmacy

These are prescription-only medicines. The only legal route to either tirzepatide or semaglutide for weight management is a clinical assessment followed by a prescription from a registered prescriber. That can happen through an NHS pathway (eligibility criteria for NHS tirzepatide are strict and phased, and waiting lists for specialist semaglutide services are commonly long) or through a regulated private pharmacy.

If you are considering the private route, the single most important check is whether the pharmacy appears on the GPhC register. You can verify any online pharmacy at the GPhC pharmacy register. The MHRA has issued repeated warnings about fake weight-loss pens sold online, some of which have contained insulin rather than the stated medicine. A discount or a seller offering these medicines without a clinical consultation is a warning sign, not a saving.

Thinking about costs as part of this decision? Our guide to weight-loss injection costs in the UK sets out what private treatment typically includes, and what cheaper-looking prices often leave out. When you're ready to look at whether either medicine could be right for you, checking your eligibility through a free consultation is the place to start.